secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001493152-26-016981
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain
--------------------------------------------------------------------------------

- Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.
- Non-cash gain of $365.4M from fair value increase in GMP Bio JV investment, partially offset by $111.6M deferred tax provision.
- JV subsidiaries Sapu Bio and Sapu Nano formalized; OT-101 Phase 1 combo trial completed and Phase 2/3 pancreatic cancer enrolling.
- Deciparticle nanoparticle platform advancing six candidates; everolimus trial enrolling in Australia, INDs expected for palbociclib and docetaxel in 2026.
- PDAOAI AI platform expanded to over 100,000 curated abstracts, contributing to seven peer-reviewed publications in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315226016981/0001493152-26-016981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315226016981/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-016981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer